Having trouble accessing articles? Reset your cache.

Ibrutinib receives third breakthrough designation

Pharmacyclics Inc. (NASDAQ:PCYC) said FDA granted breakthrough drug designation to ibrutinib to treat chronic lymphocytic leukemia

Read the full 161 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE